Johnson & Johnson Launches First PARP Combo to Boost HRR-altered mCSPC Care
June 3, 2025
Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptoms